Navigation Links
A Biologic Drug Superior to Spiriva in Reducing COPD-Related Exacerbations Would Earn a Higher Patient Share in Europe Than in the U.S.
Date:1/12/2009

Spiriva Will Remain the Gold Standard Treatment Through 2017, According to a New Report from Decision Resources.

WALTHAM, Mass., Jan. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a biologic drug that is superior to Boehringer Ingelheim/Pfizer's Spiriva in reducing yearly COPD-related exacerbations would earn a higher patient share in Europe (30 percent) than in the U.S. (15 percent) according to surveyed European and U.S. pulmonologists. COPD-related exacerbations are episodic events often requiring hospitalization.

"A biological drug that provides fewer yearly COPD-related exacerbations compared to current therapies holds much commercial promise," said Regina Jammen, M.S., analyst at Decision Resources. "Enthusiasm from U.S. and European pulmonologists for a biologic drug with the potential to dramatically reduce yearly exacerbation rates likely reflects physicians' recognition of not only the long-term therapeutic benefits of such a drug, but also its economic benefits."

The new report entitled Chronic Obstructive Pulmonary Disease: Blockbuster Potential Exists for Biologic Drugs That Dramatically Reduce Exacerbation Rates finds that Spiriva will remain Decision Resources' clinical gold standard treatment for COPD over the next eight years even though emerging drugs such as Forest/Almirall's aclidinium, Novartis's indacaterol, Boehringer Ingelheim's BI-1744/tiotropium and Nycomed/Mitsubishi Tanabe's roflumilast will offer therapeutic benefits to COPD patients.

About the Report

Chronic Obstructive Pulmonary Disease: Blockbuster Potential Exists for Biologic Drugs That Dramatically Reduce Exacerbation Rates is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need,
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Biologic treatment for rheumatoid arthritis and the risk of cancer
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Neurobiological Technologies Reports Going Concern Qualification
4. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
5. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
6. Study questions assumptions about human sensitivity to biological motion
7. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
8. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
9. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
10. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
11. CalbaTech Reports That LifeStems Biologics License Has Been Renewed

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...HINGTON, Nov. 9 The Churchill Ce...ward For Leadership to J.W. "Bill" Marriott for hi...gh progressive free market practices and fostering...Mr. Marriott will receive his award at a ceremony ...on D.C. Four Seasons Hotel. ,, "This is a test...
(Date:11/9/2009)... ANGELES, Nov. 9 Tracy Anderson, t...nd Kate Hudson, will be hosting two events at her ...Finally sharing her long awaited Nutritional Meal ...ng her TA Baby Food Cleanse and Lifestyle Menu. S...porates her entire method of cardio and muscle str...
(Date:11/9/2009)...y be left atrial enlargement, study finds , ...s a major risk factor for left atrial enlargement,...stroke and death, a new study shows. , Atrial f...(an irregular heart rhythm or heartbeat). , Re...ed 25 to 74, in Germany who were followed for 10 y...
(Date:11/9/2009)... Studying Genetic Variance Across ... of Genes , (Vocus) Novem...tries can be extraordinarily valuable when analyzi...-center genetics study that scanned the genomes ...regional differences, Drs. Chao Tian and Michael F...
(Date:11/9/2009)...ly due to fact that both eye conditions are age-re...9 (HealthDay News) -- Cataract surgery doesn,t app...r degeneration (AMD), according to a new study tha... vision loss worsens the other. , "Because both...uals with cataract also have AMD," wrote Li Ming D...
Breaking Medicine News(10 mins):Health News:J.W. 'Bill' Marriott to Receive Churchill Centre Award For Leadership 2Health News:Celebrity Trainer Tracy Anderson Sharing Her Fitness and Diet Secrets This Week 2Health News:News from the November/December Issue of Molecular Medicine 2Health News:Cataract Surgery Doesn't Worsen Macular Degeneration: Study 2
...eam of doctors from different specialties, recentl...roach can benefit cancer patients. Dr. Peter Costa... found a rare and often fatal tumor in Angela Carr...gnosed in 2002. This type of cancer makes up about...
...ry year, more than 5 million people go to the Emer... for 20 to 30 minutes. Most receive an ECG and oth...a heart attack or other serious heart problems. Ho...in. Researchers suggest// that about 2 percent of ...
...riasis patients who have been long-awaiting new op...ood and Drug Administration's approval of the new ...immune cells to control hard-to-treat psoriasis. P...that are currently available for psoriasis range f...
...ple have been concerned, for many decades now, abo...e smile. But tooth discolouration is a persistent ...les in food and drink. Back in the Middle Ages, pe...red many easy and ingenuous ways of maintaining te...
...ecent study has has shown that oxygen, apart from ... Prior studies have shown that oxygen plays an imp.... In fact, studies have shown treatment in a hyper...ity. The researchers of the new have now suggested...
...nking milk has always been associated with good he...o drink milk to grow up healthy. However, a recent... well established fact(or is it still?). A study i...ein and the national rate of heart disease and ins...
Other Medicine News:Health News:New and unique treatment for Psoriasis patients 2
(Date:11/9/2009)..., AUSTIN, Texas, Nov. 9 Celli...rs, is collaborating with Tissue Genesis, Inc. to ... derived adult stem cells. SpineSmith acquired th...se (fat) tissue derived stem cell technology in No...this new exclusive agreement allows Celling Techno...
(Date:11/9/2009)..., ST. LOUIS, Nov. 9, 2009 /PRNewswire-FirstCa...nc (NYSE: PFE ) today announced that they have en...izer,s Chesterfield Village Research Center locate...eement, Monsanto will acquire the property from Pf...izer will continue to have operations at Chesterfi...
(Date:11/9/2009)..., PISCATAWAY, N.J., Nov. 9 /PRNewswire-FirstC...ard: MLSS), the recognized leader in computer-cont...t it will be showcasing its patented, award-winnin...ystem) at the Madow Group,s 15th year of TBSE tit... place at the Las Vegas Hilton. ,, The STA S...
Breaking Medicine Technology:Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes 2Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes 3Monsanto to Purchase Chesterfield Village Research Center From Pfizer 2Monsanto to Purchase Chesterfield Village Research Center From Pfizer 3Milestone Scientific to Exhibit at the 15th Anniversary of TBSE (The Best Seminar Ever) in Las Vegas 2Hard to Treat Diseases Inc 28HTDS 29 Reports on Ribavirin Research as Potential Treatment for MS 52558 1Hard to Treat Diseases Inc 28HTDS 29 Reports on Ribavirin Research as Potential Treatment for MS 52558 2Hard to Treat Diseases Inc 28HTDS 29 Reports on Ribavirin Research as Potential Treatment for MS 52558 3Video of EpiDerm Skin Irritation Test 28SIT 29 Method Now Available 13170 1Video of EpiDerm Skin Irritation Test 28SIT 29 Method Now Available 13170 2Twinlabs 28R 29 Mobile Beach Bash Heats Up After a Successful Kick Off of the 2009 RateYourAbs com Contest 52549 1Twinlabs 28R 29 Mobile Beach Bash Heats Up After a Successful Kick Off of the 2009 RateYourAbs com Contest 52549 2
....Y.--(BUSINESS WIRE)--Jun 18, 2007 - Advanced Vira...iopharmaceutical,company, announced today that pre...ological study show topical treatment with AVR118,...ammation and,redness associated with surgical inci...open label dermatological study is evaluating the,...
...an 70 abstracts highlight VELCADE efficacy in broa...-, CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-Fir...announced that data for,VELCADE, the market leadin...or patients with previously treated multiple myelo...ional Myeloma,Workshop (IMW) in Kos, Greece, June ...
Other Medicine Technology:Advanced Viral Research Corp. Announces Positive Preliminary,Findings from Ongoing Phase II Dermatological Study 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 3Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 4Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 5Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 7Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 8
DeepLight Glaucoma Treatment System
Verity Adx Pacemaker
Regency Pacemaker
Identity® Adx Pacemaker
Medicine Products: